UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-38599 Aquestive Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 30 Technolog ...

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q2 2020 Results Earnings Conference Call August 5, 2020 8:00 AM ET Company Participants Stephanie Carrington - IR, Westwicke Keith Kendall - President and Chief Executive Officer John Maxwell - SVP and Chief Financial Officer Daniel Barber - SVP and Chief Operating Officer Ken Marshall - SVP and Chief Commercial Officer Conference Call Participants Rafay Sardar - BMO Capital Markets Shveta Dighe - Wedbush Securities, Inc. Jason Butler - JMP Securities Thomas Flaten ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-38599 Aquestive Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 30 Technology Dri ...

Aquestive Therapeutics, Inc. (HEI) Q1 2020 Earnings Conference Call May 7, 2020 8:00 AM ET Company Participants Stephanie Carrington - Westwicke, IR Keith Kendall - CEO, President and Director John Maxwell - CFO Daniel Barber - COO Ken Marshall - CCO Conference Call Participants Rafay Sardar - BMO Capital Markets Randall Stanicky - RBC Capital Markets Liana Moussatos - Wedbush Securities Jason Butler - JMP Securities Thomas Flaten - Lake Street Capital Blair Cohen - H.C. Wainwright Operator Good morning, an ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to Commission File Number: 001-38599 Aquestive Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 30 Technology Drive, W ...

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2019 Earnings Conference Call March 12, 2020 8:00 AM ET Company Participants Stephanie Carrington - Westwicke Investor Relations Keith Kendall - Chief Executive Officer John Maxwell - Chief Financial Officer Conference Call Participants Gary Nachman - BMO Capital Markets Dan Busby - RBC Capital Markets Roy Buchanan - JMP Securities Liana Moussatos - Wedbush Securities Thomas Flaten - Lake Street Capital Markets Edward White - H.C. Wainwright Operator Good mornin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share AQST NASDAQ Global Market FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ C ...